News

Research of Zoledronic acid

  • Author:Hubei Ocean Biotech Co,.LTd
  • Source:www.oceanchinachem.com
  • Release on :2016-06-12

Zoledronic acid has been found to have a direct antitumor effect and to synergistically augment the effects of other antitumor agents in osteosarcoma cells.

Zoledronate has shown significant benefits versus placebo over three years, with a reduced number of vertebral fractures and improved markers of bone density.]An annual dose of zoledronic acid may also prevent recurring fractures in patients with a previous hip fracture.

Zoledronate also attenuates accumulation of DNA damage in mesenchymal stem cells and protects their function.Given this characteristic, its potential to affect conditions arising from stem-cell dysfunction makes it a promising medicine for a range of age-related disease.


An increase in Disease-Free Survival (DFS) was found in the ABCSG-12 trial, in which 1,803 premenopausal women with endocrine-responsive early breast cancer receivedanastrozole with zoledronic acid.[19] A retrospective analysis of the AZURE trial data revealed a DFS survival advantage, particularly where estrogen had been reduced.

In a meta-analysis of trials where upfront zoledronic acid was given to prevent aromatase inhibitor-associated bone loss, active cancer recurrence appeared to be reduced.[21] The results of clinical studies of adjuvant treatment on early-stage hormone-receptor-positive breast-cancer patients under hormonal treatment – especially with the bisphosphonate zoledronic acid – caused excitement because they demonstrated an additive effect on decreasing disease relapses at bone or other sites. A number of clinical and in vitro and in vivo preclinical studies, which are either ongoing or have just ended, are investigating the mechanism of action and antitumoral activity of bisphosphonates.Ongoing large trials testing bisphosphonates as adjuvant treatment in breast cancer include NSABP B-34, the NATAN trial.and SWOG-S0307.[24] A 2010 review concluded that "adding zoledronic acid 4 mg intravenously every 6 months to endocrine therapy in premenopausal women with hormone receptor-positive early breast cancer ... is cost-effective from a US health care system perspective"



How to choose a quality and trustable
 a Zoledronic acid supplier?HBOCEAN,as a professional supplier of pharmaceutical raw materials within 10-year experience,always persist in the management purpose of "Quality First and Credit Supremacy" and the management ideas of "Honesty and Win-Win".Nowadays,we have gained good reputation at domestic and abroad market. Don't be hesitated to contact us.